As an effective arthritis inhibitor, GlcN has been proved to suppress the activation of nucleotide-binding oligomerization domain-like receptor containing pyrin domain 3 (NLRP3) inflammasome in mouse and human macrophages. Here, NLRP3 is linked to arthritic joint disease.